Oligonucleotides, Antisense

"Oligonucleotides, Antisense" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Short fragments of DNA or RNA that are used to alter the function of target RNAs or DNAs to which they hybridize.

Descriptor ID	D016376
MeSH Number(s)	D13.150.480 D13.444.600.150.640 D13.695.578.424.480 D27.720.470.530.600.150.640
Concept/Terms	Oligonucleotides, Antisense Oligonucleotides, Antisense Antisense Oligonucleotides Anti-Sense Oligonucleotides Anti Sense Oligonucleotides Oligonucleotides, Anti-Sense

Below are MeSH descriptors whose meaning is more general than "Oligonucleotides, Antisense".

Chemicals and Drugs [D]
Nucleic Acids, Nucleotides, and Nucleosides [D13]
Antisense Elements (Genetics) [D13.150]
Oligonucleotides, Antisense [D13.150.480]
Nucleic Acids [D13.444]
Nucleic Acid Probes [D13.444.600]
Antisense Elements (Genetics) [D13.444.600.150]
Oligonucleotides, Antisense [D13.444.600.150.640]
Nucleotides [D13.695]
Polynucleotides [D13.695.578]
Oligonucleotides [D13.695.578.424]
Oligonucleotides, Antisense [D13.695.578.424.480]
Chemical Actions and Uses [D27]
Specialty Uses of Chemicals [D27.720]
Laboratory Chemicals [D27.720.470]
Molecular Probes [D27.720.470.530]
Nucleic Acid Probes [D27.720.470.530.600]
Antisense Elements (Genetics) [D27.720.470.530.600.150]
Oligonucleotides, Antisense [D27.720.470.530.600.150.640]

Below are MeSH descriptors whose meaning is related to "Oligonucleotides, Antisense".

Below are MeSH descriptors whose meaning is more specific than "Oligonucleotides, Antisense".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Oligonucleotides, Antisense" by people in this website by year, and whether "Oligonucleotides, Antisense" was a major or minor topic of these publications.

Bar chart showing 87 publications over 26 distinct years, with a maximum of 8 publications in 2018

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1995	2	1	3
1996	3	0	3
1998	0	2	2
2001	1	1	2
2002	3	2	5
2003	2	3	5
2004	0	2	2
2005	2	5	7
2006	1	2	3
2007	1	0	1
2008	1	0	1
2009	1	0	1
2010	1	1	2
2011	3	2	5
2012	1	2	3
2014	1	2	3
2015	1	2	3
2016	3	1	4
2017	1	1	2
2018	6	2	8
2019	1	1	2
2021	4	0	4
2022	5	2	7
2023	1	2	3
2024	3	1	4
2025	1	1	2

Below are the most recent publications written about "Oligonucleotides, Antisense" by people in Profiles.

Belgrad J, McConnell E, Leonard S, Nolen N, Lauffer MC, Watts JK, Yu T, Yan WX, Aartsma-Rus A. The N=1 Collaborative: advancing customized nucleic acid therapies through collaboration and data sharing. Nucleic Acids Res. 2025 Apr 22; 53(8).

View in: PubMed
Jung S, Richter JD. Trinucleotide repeat expansion and RNA dysregulation in fragile X syndrome: emerging therapeutic approaches. RNA. 2025 Feb 19; 31(3):307-313.

View in: PubMed
Moazami MP, Rembetsy-Brown JM, Sarli SL, McEachern HR, Wang F, Ohara M, Wagh A, Kelly K, Krishnamurthy PM, Weiss A, Marosfoi M, King RM, Motwani M, Gray-Edwards H, Fitzgerald KA, Brown RH, Watts JK. Quantifying and mitigating motor phenotypes induced by antisense oligonucleotides in the central nervous system. Mol Ther. 2024 Dec 04; 32(12):4401-4417.

View in: PubMed
Susorov D, Echeverria D, Khvorova A, Korostelev AA. mRNA-specific readthrough of nonsense codons by antisense oligonucleotides (R-ASOs). Nucleic Acids Res. 2024 Aug 27; 52(15):8687-8701.

View in: PubMed
Sarli SL, Fakih HH, Kelly K, Devi G, Rembetsy-Brown JM, McEachern HR, Ferguson CM, Echeverria D, Lee J, Sousa J, Sleiman HF, Khvorova A, Watts JK. Quantifying the activity profile of ASO and siRNA conjugates in glioblastoma xenograft tumors in vivo. Nucleic Acids Res. 2024 May 22; 52(9):4799-4817.

View in: PubMed
Sharma VK, Mangla P, Singh SK, Prasad AK. Triazole-linked Nucleic Acids: Synthesis, Therapeutics and Synthetic Biology Applications. Curr Org Synth. 2024; 21(4):436-455.

View in: PubMed
Engelbeen S, O'Reilly D, Van De Vijver D, Verhaart I, van Putten M, Hariharan V, Hassler M, Khvorova A, Damha MJ, Aartsma-Rus A. Challenges of Assessing Exon 53 Skipping of the Human DMD Transcript with Locked Nucleic Acid-Modified Antisense Oligonucleotides in a Mouse Model for Duchenne Muscular Dystrophy. Nucleic Acid Ther. 2023 12; 33(6):348-360.

View in: PubMed
Shah S, Sharp KJ, Raju Ponny S, Lee J, Watts JK, Berry-Kravis E, Richter JD. Antisense oligonucleotide rescue of CGG expansion-dependent FMR1 mis-splicing in fragile X syndrome restores FMRP. Proc Natl Acad Sci U S A. 2023 07 04; 120(27):e2302534120.

View in: PubMed
Braatz C, Komes MP, Ravichandran KA, de Fragas MG, Griep A, Schwartz S, McManus RM, Heneka MT. NLRP3-directed antisense oligonucleotides reduce microglial immunoactivities in vitro. J Neurochem. 2024 Oct; 168(10):3467-3481.

View in: PubMed
Goyenvalle A, Jimenez-Mallebrera C, van Roon W, Sewing S, Krieg AM, Arechavala-Gomeza V, Andersson P. Considerations in the Preclinical Assessment of the Safety of Antisense Oligonucleotides. Nucleic Acid Ther. 2023 01; 33(1):1-16.

View in: PubMed

People

Explore

Similar Concepts

Top Journals